Quantification of residual disease in chronic myeloid leukemia patients treated by interferon using interphase FISH and competitive RT-PCR

被引：0
|
作者：
Tchirkov, A
Giollant, M
Briancon, G
Travade, P
Tournilhac, O
Demeocq, F
Kuleshov, N
Malet, P
机构：
[1] UNIV AUVERGNE,FAC MED,CLERMONT FERRAN,FRANCE
[2] PEDIAT RES INST HEMATOL,MOSCOW,RUSSIA
来源：
CYTOGENETICS AND CELL GENETICS | 1997年 / 77卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：P325 / P325
页数：1
相关论文
共 50 条
  • [41] Monitoring of minimal residual disease of patients with chronic myeloid leukemia (CML) treated with imatinib
    Herrera, P.
    Calbacho, M.
    Ramos, M. L.
    Heras, C.
    Ferro, M. T.
    Cabello, P.
    Villalon, L.
    Lopez, J.
    Odriozola, J.
    CHROMOSOME RESEARCH, 2005, 13 : 194 - 194
  • [42] Cytogenetic and Molecular Analyses of Philadelphia Chromosome Variants in CML (Chronic Myeloid Leukemia) Patients from Sindh using Karyotyping and RT-PCR
    Ujjan, Ikram Din
    Akhund, Anwar Ali
    Saboor, Muhammad
    Qureshi, Muhammad Asif
    Khan, Saeed
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2015, 31 (04) : 936 - 940
  • [43] ARE YOU ACTUALLY SUSPECTING A CHRONIC MYELOID LEUKEMIA WHEN ORDERING A BCR/ABL RT-PCR?
    Abalo Perez, L.
    Guillen Rienda, C.
    Sopena Corvinos, M.
    Torres Jimenez, W. M.
    Guillen Santos, R.
    Villarrubia, J.
    Gonzalez Fernandez, F. A.
    Cava Valenciano, F.
    HAEMATOLOGICA, 2017, 102 : 724 - 724
  • [44] Quantification of residual disease in chronic myelogenous leukemia (CML) patients on interferon-alpha therapy by competitive polymerase chain reaction.
    Hochhaus, A
    Reiter, A
    Skladny, H
    Lin, F
    Mason, PJ
    vanRhee, F
    Shepherd, PCA
    Allan, NC
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    BLOOD, 1995, 86 (10) : 1064 - 1064
  • [45] Quantification of minimal residual disease in patients with acute promyelocytic leukemia (APL) by real time quantitative RT-PCR with specific fluorescent hybridization probes.
    Mitterbauer, A
    Mannhalter, C
    Jaeger, U
    Kalhs, P
    Lechner, K
    Mitterbauer, G
    LEUKEMIA, 2001, 15 (12) : 2022 - 2022
  • [46] Quantification of minimal residual disease in patients with acute promyelocytic leukemia (APL) by real time quantitative RT-PCR with specific fluorescent hybridization probes.
    Mitterbauer, A
    Mannhalter, C
    Jäger, U
    Kalhs, P
    Lechner, K
    Mitterbauer, G
    BLOOD, 2000, 96 (11) : 313A - 313A
  • [47] Detection of minimal residual disease using real-time RT-PCR in MLL/AF9 -: Positive acute myeloid leukemia.
    Scholl, C
    Breitinger, H
    Frohling, S
    Schlenk, RF
    Dohner, H
    Dohner, K
    BLOOD, 2003, 102 (11) : 376A - 376A
  • [48] Multimarker RT-PCR for detection of minimal residual disease in breast cancer patients
    Rebecca Ireland
    Nature Clinical Practice Oncology, 2006, 3 (6): : 293 - 293
  • [49] Monitoring of minimal residual disease (MRD) by RT-PCR in childhood acute myeloid leukemia (AML) with AML1/ETO rearrangement
    Viehmann, S
    Creutzig, U
    Borkhardt, A
    Harbott, J
    LEUKEMIA, 2001, 15 (12) : 2025 - 2025
  • [50] Interferon beta bioavailability in Multiple Sclerosis patients: A quantitative competitive RT-PCR determination of MxA mRNA
    Malucchi, S
    Castello, A
    Gilli, F
    Sala, A
    Bertolotto, A
    NEUROLOGY, 2001, 56 (08) : A361 - A361
12345